JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

TfR1 CapX, a BBB-penetrant and uniquely human-focused AAV capsid targeting the central nervous system (CNS), demonstrates robust, brain-wide delivery via intravenous injection FDA-supported TfR1 ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today ...

Affinia will also present data on its engineered capsids that target receptor-Y, a novel human brain receptor, to enable AAV crossing of the blood-brain barrier.

JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication Voyager Therapeutics, Inc. Thu, May 15, 2025, 7:00 AM 6 min read ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetic ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the ...